A protein hydrogel for wound healing and bone cell viability and process of preparing thereof
Patent Information
- Application Number
- IN202531107639
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2025-11-06
- Publication Date
- 2026-10-23
- Estimated Expiration
- 2045-11-06
AI Technical Summary
Existing hydrogels face issues with viscosity reduction due to exposure to wound fluid, leading to loss of gel integrity, and lack dual applicability in wound healing and bone tissue regeneration, with unfolded or aggregated proteins causing cytotoxicity and immune responses.
A protein aggregate-based hydrogel with a primary structural framework of unfolded and aggregated proteins encapsulating hyaluronic acid, providing enhanced porosity, water-holding capacity, and hemocompatibility, promoting bone cell proliferation and regeneration.
The hydrogel exhibits superior osteogenic potential, accelerated wound healing, and improved cell survival rates, with reduced cytotoxicity and adverse blood interactions, facilitating faster healing and bone tissue integration.
Abstract
Description
FIELD OF THE INVENTION The present invention relates to the field of hydrogels for treatment of wounds, and more particularly, to a protein aggregate hydrogel for wound healing and bone cell viability.BACKGROUND OF THE INVENTION Glycan-based hydrogels, particularly derived from natural polysaccharides such as hyaluronic acid (HA), chitosan, alginate, and cellulose derivatives, are widely utilized in wound healing and tissue regeneration due to their high water absorption, biocompatibility, low immunogenicity, and ability to mimic the extracellular matrix, thereby promoting cell proliferation, angiogenesis, and tissue remodeling [1-3]. The protein hydrogels, sourced from natural proteins like collagen, gelatin, fibrin, elastin, sericin, and keratin or engineered recombinant proteins such as elastin-like polypeptides and silk fibroin, offer tunable mechanical properties, bioactive motifs, and biodegradability, making them effective scaffolds for wound repair, drug delivery, and tissue engineering [4-6]. However, unfolded or aggregated proteins-commonly arising from protein misfolding-are traditionally considered unsuitable for biomedical use due to their tendency to expose hydrophobic domains, induce cytotoxicity, trigger immune responses, and generate anti-protein antibodies [7,8]. This has led to their disposal as biological sites, despite their inherent structural stability. Further, there exist no existing hydrogel that combines a sustainable aggregated-protein backbone with encapsulated HA to exploit the mechanical resilience of protein aggregates alongside the hydration, hemocompatibility, porosity, and osteogenic potential conferred by HA. This absence in the literature defines a critical research gap: which is the upcycling of aggregated proteins into functional, bioactive hydrogels with dual applicability in wound healing and bone tissue regeneration, which could establish a new paradigm in sustainable biomaterial design [9-11].References[1] Wang, R. et al. The design principle of natural polysaccharide hydrogels for promoting wound healing: a prospective review. Journal of Material Chemistry B, 2025.[2] Ahmed, E. M. Hydrogel: Preparation, characterization, and applications. Journal of Advanced Research, 2015. [3] Collins, M. N., Birkinshaw, C. Hyaluronic acid-based scaffolds for tissue engineering-A review. Carbohydrate Polymers, 2013. [4] Li, J., Mooney, D. J. Designing hydrogels for controlled drug delivery. Nature Reviews Materials, 2016. [5] Li, L. et al. Protein-based hydrogels and their biomedical applications. Advanced Healthcare Materials, 2023. [6] Wang, H. et al. Silk-based biomaterials in biomedical applications. Materials Today, 2022. [7] Dobson, C. M. Protein folding and misfolding. Nature, 2003. [8] Singh, S. K. et al. Immunogenicity of protein aggregates-Concerns and realities. Biotechnology Advances, 2011. [9] Knowles, T. P. J., Mezzenga, R. Amyloid fibrils as building blocks for natural and artificial functional materials. Advanced Materials, 2016.
[10] Arif, Z., Ding, J. Additive manufacturing of sustainable biomaterials for biomedical applications. Asian Journal of Pharmaceutical Sciences, 2021.
[11] Rana, M. et al. Evolution of Hybrid Hydrogels: Next-Generation Biomaterials for Drug Delivery and Tissue Engineering. Gels, 2024. Various patent literature on this subject area will now be discovered one by one: Patent publication US granted patent number 7083806 discloses Wound Gels for healing wounds. Another patent publication WO published application number 2024120364 discloses Glycan based hydrogel for wound healing. Patent publication WO published application number 2020181356A1 / US published application number 20220168335 discloses Hyaluronic acid derivatives for wound healing. Patent publication EP published application number 4368208 discloses Novel HA-based hydrogels (2024 divisional). Patent publication Chinese publication number 109045349 discloses Hydrogel skin dressing with low-molecular-weight HA and herbal extracts. Another Chinese patent number 103191461 discloses Dual molecular weight HA dressing with silver nitrate and PEG. Patent publication Chinese publication number 104840428 discloses HA-chitosan microsphere system with epidermal growth factor. To summarize, the main problem with known hydrogels is that exposure to fluid released from the wound causes an exponential reduction of viscosity of the gel, leading to loss of gel integrity and, if left in place on the wound, will exacerbate tissue (both wound and normal skin) maceration. Further, there are no existing bioactive hydrogels with dual applicability in wound healing and bone tissue regeneration. Therefore, the present invention provides a protein aggregate-based hydrogel for wound healing, bone tissue regeneration and bone cell viability.OBJECTIVE OF THE INVENTION The primary objective of the invention is to provide a protein aggregate-based hydrogel for wound healing, bone tissue regeneration and bone cell viability. Another objective of the invention is to provide a hydrogel with improved cell survival rates, accelerating wound closure and regeneration. Yet another objective of the invention is to provide hydrogel with superior hemocompatibility, minimizing adverse blood-material interactions and promoting safer in vivo application. Yet another objective of the invention is to provide hydrogel with higher porosity that facilitates efficient nutrient and oxygen diffusion, site removal, and cell infiltration, collectively contributing to faster healing dynamics and more robust tissue integration. Yet another objective of the invention is to provide a process for synthesizing the protein hydrogel which is easy, inexpensive and user friendly. SUMMARY OF THE INVENTION The present invention relates to a protein hydrogel for wound healing comprising: a primary structural framework of a proteinaceous matrix, the proteinaceous matrix constituted of unfolded and aggregated proteins; and a glycan encapsulated within the proteinaceous matrix. In particular, the protein hydrogel exhibits enhanced porosity, superior water-holding capacity, and improved hemocompatibility. In various embodiments of the present invention, the glycan is hyaluronic acid. Further, the protein hydrogel is transparent in nature. In accordance with an embodiment of the present invention, the protein hydrogel is a composite protein glycan hydrogel. In accordance with an embodiment of the present invention, the protein hydrogel is a protein hyaluronic acid hydrogel. In accordance with an embodiment of the present invention, the protein hydrogel exhibits increased swelling behavior in water, physiological buffer at pH 7.4 and simulated wound fluid. In accordance with an embodiment of the present invention, the hydrogel demonstrates reduced reactive oxygen species (ROS) generation in DCFH-DA staining analyses. In accordance with an embodiment of the present invention, an encapsulated hyaluronic acid imparts growth factor-binding capability and enhanced osteogenic potential to support bone cell proliferation and regeneration. In accordance with an embodiment of the present invention, the protein hydrogel is biocompatible and suitable for biomedical applications including wound healing, bone cell viability, tissue engineering, and regenerative medicine. Another embodiment of the present invention relates to a process for synthesizing the protein hydrogel. The process comprising steps of preparing a proteinaceous solution by taking 70 mg / ml of protein from a protein source; heating the proteinaceous solution at 850 C for 10 minutes for partially unfolding the protein; adding a reducing agent for complete unfolding of the protein by reducing the disulfide bonds; wherein the reducing agent is 200 mM Dithiothreitol; aggregating the proteins by stirring at 1000 rpm to form a proteinaceous framework; adding hydrogen peroxide to the solution for the crosslinking of the protein through the oxidative crosslinking process; wherein concentration of hydrogen peroxide is 200 mM; incorporating hyaluronic acid within the proteinaceous framework to form a composite protein glycan hydrogel. This together with the other aspects of the present invention along with the various features of novelty that characterize the present disclosure is pointed out with particularity. For a better understanding of the present disclosure, its operating advantages, and the specified objective attained by its uses, reference should be made to the accompanying descriptive matter in which there are illustrated exemplary embodiments of the present invention.DESCRIPTION OF THE DRAWINGS The advantages and features of the present invention will become better understood with reference to the following detailed description taken in conjunction with the accompanying drawings, in which:Embodiments of the present invention will be described in detail based on the following Fig. 1A illustrates a scheme for preparation of the BMP-2 hydrogel according to embodiments as disclosed herein. Fig. 1B illustrates a scheme for preparation of the BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 1C illustrates a pictorial snapshot of the gelation process in BMP-2 hydrogel according to embodiments as disclosed herein. Fig. 1D illustrates a schematic gelation process in BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 2 illustrates FTIR spectra of the protein and the hydrogels, according to various embodiments of the present invention. Fig. 3A illustrates time sweep rheological analysis of BMP-2 hydrogel according to embodiments as disclosed herein. Fig. 3B illustrates time sweep rheological analysis of BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 3C illustrates angular frequency sweep rheological analysis of BMP-2 hydrogel according to embodiments as disclosed herein. Fig. 3D illustrates angular frequency sweep rheological analysis of BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 3E illustrates complex viscosity of the hydrogel with respect to time according to embodiments as disclosed herein. Fig. 3F illustrates the complex viscosity of the hydrogel with respect to frequency according to embodiments as disclosed herein. Fig.4A shows swelling characteristics of BMP-2 and BMP-2 / HA hydrogels in double-distilled water according to embodiments as disclosed herein. Fig. 4B shows swelling characteristics of BMP-2 and BMP-2 / HA hydrogels in the PBS buffer (pH 7.4) according to embodiments as disclosed herein. Fig. 4C shows swelling characteristics of BMP-2 and BMP-2 / HA hydrogels in simulated wound fluid according to embodiments as disclosed herein. Fig.4D shows a histogram of swelling behavior between water and simulated wound fluid according to embodiments as disclosed herein. Fig. 5A demonstrates FESEM characterization of BMP-2 hydrogel according to embodiments as disclosed herein. Fig. 5B demonstrates FESEM characterization of BMP-2 / HA composite hydrogel according to embodiments as disclosed herein. Fig. 5C demonstrates pore size distribution diameter of the pores of BMP-2 hydrogel and BMP-2 / HA composite hydrogel according to embodiments as disclosed herein. Fig. 6A demonstrates hemocompatibility evaluation of hydrogels having absorbance intensities at 540 nm according to embodiments as disclosed herein. Fig. 6B demonstrates visual comparison of samples after hemolysis testing according to embodiments as disclosed herein. Fig.7A illustrates a pictorial snapshot of Trypan blue biocompatibility assay showing gut cell viability in Drosophila larvae. Fig. 7B illustrates a pictorial snapshot of AO-ETBR assay to detect the cell death according to embodiments as disclosed herein. Fig. 7C illustrates a pictorial snapshot of DAPI- DCFH-DA assay to detect nuclear fragmentation and ROS generation according to embodiments as disclosed herein. Fig. 8A illustrates pictorial snapshots of wound healing in Drosophila melanogaster according to embodiments as disclosed herein. Fig. 8B illustrates quantitative plot representation of wound closure percentage over time according to embodiments as disclosed herein. Fig. 9 demonstrates Cytocompatibility assay (MTT) showing cell viability test of L929 fibroblast cells in the presence of BMP-2 and BMP-2 / HA hydrogels in L292 cell line according to embodiments as disclosed herein. Fig.10 illustrates a process of synthesizing a protein hydrogel, according to various embodiments of the present invention. Like numerals denote like elements throughout the figures.DESCRIPTION OF THE INVENTION The exemplary embodiments described herein detail for illustrative purposes are subjected to many variations. It should be emphasized, however, that the present invention is not limited to as disclosed. It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient, but these are intended to cover the application or implementation without departing from the spirit or scope of the present invention. Specifically, the following terms have the meanings indicated below. The terms "a" and "an" herein do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced items. Terms hydrogel and protein hydrogel are used simultaneously for convenience throughout the draft. The inventive aspects of the invention, along with various components and engineering involved, will now be explained with reference to FIGS. 1-10 herein. Embodiments herein disclose a protein hydrogel for wound healing comprising: a primary structural framework of a proteinaceous matrix and a glycan encapsulated within the proteinaceous matrix. In particular, the protein hydrogel exhibits enhanced porosity, superior water-holding capacity, and improved hemocompatibility. Moreover, glycan is hyaluronic acid. In the protein hydrogel the glycans-specifically hyaluronic acid-are encapsulated within the protein matrix. Uniquely, the protein framework is composed of unfolded and aggregated proteins, offering a sustainable strategy for repurposing aggregated proteins in biomedical applications. Further, the protein hydrogel exhibits superior osteogenic potential, providing enhanced nourishment and support for bone cell proliferation and regeneration. The protein matrix is composed of deliberately utilized unfolded and aggregated proteins, transforming a typically undesirable or waste biomaterial into a sustainable, value-added structural component for biomedical applications. This aligns with principles of resource efficiency and waste valorization and also creates a synergistic material platform wherein the mechanical integrity and tunable properties of the protein aggregates are coupled with the hydration, bioactivity, and growth factor-binding capabilities of hyaluronic acid. The resulting hydrogel exhibits a dual functional advantage-retaining the established wound-healing efficacy of glycans while offering superior osteogenic potential and enhanced bone cell nourishment, thereby extending its applicability into orthopedic and regenerative medicine domains in a manner not anticipated by existing technologies. The following brief definition of terms shall apply throughout the present disclosure: AO-ETBR assay- Acridine orange and Ethidium Bromide Assay BMP-2 refers to BMP-2 (Bone Morphogenetic Protein-2) "pET41b" stands for a specific pET plasmid vector, a widely used tool for protein expression in Escherichia coli (E. coli) cells. The "pET" signifies "plasmid expression in E. coli," and the "41b" designation refers to a specific series of these plasmids, in this case designed for cloning and high-level expression of peptide sequences fused with a GST protein Fig. 1A and Fig. 1 B illustrate a scheme for preparation of the BMP-2 hydrogel and BMP-2 / HA hydrogel according to embodiments as disclosed herein. Bone Morphogenetic Protein-2, with its 7 cysteine residues per molecule, is well-equipped for disulfide bond cross-linking, which is instrumental in protein hydrogel formation. Before initiating protein hydrogel synthesis, BMP-2 is pre-treated with heat at 85°C for a brief period of 10 minutes and treated with 15 mM dithiothreitol (DTT) to denature the proteins, evaluate hydrophobic interactions that might lead to irreversible aggregation, and uncover the free cysteines for subsequent cross-linking. Further, a redox cycle previously described by Ogden and Guan, which involves the rapid oxidation of free thiol groups by hydrogen peroxide (H₂O₂), resulting in the formation of disulfide cross-links between protein molecules and inducing a sol-to-gel transition. In an embodiment, BMP-2 is overexpressed using the pET41b plasmid in BL21 (DE3) and purified using the protocol established in our laboratory. Hyaluronic acid (M.W. 992.751 kD) is obtained from Dr. Uwe Freudenberg, Institute of Bio functional polymer materials, Dresden, Germany. Citric acid (maximum assay - 99.5%) is purchased from Qualigens (Thermofiscer scientific). DL- Dithiothreitol (Cleland's reagent) of purity 98% and 30% hydrogen peroxide are purchased from SRL research laboratories. pH 7.4 phosphate buffer and deionized water are used to prepare the solutions and buffers for the experiment, and all the experiments are performed in triplicates. In a preferred embodiment, to prepare hydrogel about 50-70 mg / ml (preferably 70 mg / ml) of protein is taken and the solution is briefly heated at 50-850 C (preferably 850 C) for about 10 minutes for partially unfolding the protein. After that Dithiothreitol is added in about 200 mM concentration, which acts as the reducing agent for the disulfide bonds and completely unfolds the protein and is stirred at 800-1000 rpm (ideally 1000 rpm). The hydrogen peroxide is added to the solution in about 200 mM concentration for the crosslinking of the protein through the oxidative crosslinking process. Scheme for the preparation of BMP-2 hydrogel In another embodiment, scheme for the BMP-2 / HA composite hydrogel. In an embodiment, Hyaluronic acid [HA] is incorporated in the second step (oxidation phase) of the process. In particular, the hyaluronic acid is encapsulated within the protein matrix. Uniquely, the protein framework is composed of unfolded and aggregated proteins, offering a sustainable strategy for repurposing aggregated proteins in biomedical applications. Moreover, this design exhibits superior osteogenic potential, providing enhanced nourishment and support for bone cell proliferation and regeneration. In accordance with an embodiment of the present invention, the effectiveness of hydrogels in wound healing is largely determined by their swelling properties. To evaluate the swelling capacity of these hydrogels, the weight change from their initial dried state to their fully swollen state over designated time intervals is measured. Equal-sized dried hydrogel samples, each weighing approximately 5 mg, are immersed in 50 milliliters of double-distilled water at room temperature (25°C). At specified intervals, the swollen samples are carefully extracted, excess surface water is gently blotted off using filter paper, and the samples are then weighed. This procedure is repeated until the weights of the hydrogel samples stabilized, indicating their maximum swelling capacity. The swelling ratio, also known as the degree of swelling, is calculated using the following equation:equation (1) Where Wi and Wt represent the weight of the hydrogel at the initial time and after a specific time (t), respectively. To assess the pH-responsive swelling behavior of hydrogels, their swelling capacity in buffer solutions at pH 7.4 PBS is evaluated. Investigating the swelling behavior in wound fluid is crucial, as it plays a significant role in effectively managing moisture at the wound surface. For this study, a simulated wound fluid solution is meticulously prepared by dissolving 40 mM NaCl, 3.9 mM KCl, 40 mM NaHCO3, and 2 mM CaCl2 in 1000 milliliters of deionized water. Both BMP-2 hydrogel and composite hydrogels are subsequently immersed in this solution to examine their respective swelling characteristics under standard temperature and pressure conditions. Fig. 1C and Fig. 1D illustrates the schematic gelation process in BMP-2 hydrogel and BMP-2 / HA hydrogel according to embodiments as disclosed herein. The gel formed by crosslinking only BMP-2 is opaque in nature and the gel formed by BMP-2 in the presence of the HA is transparent in nature. Fig. 2 depicts a graph of a Fourier transformed infrared (FTIR) spectra of the protein and the hydrogels according to embodiments as disclosed herein. Fourier-transform infrared (FTIR) spectroscopy is employed to investigate the functional groups, secondary structural content, and hydrophilicity of the hydrogels. The Amide I region of the FTIR spectrum provides insight into the protein's secondary structure, specifically through the carbonyl groups of peptide bonds. This spectral region enables the differentiation of secondary structures: α-helices, β-sheets, and random coils, which are typically observed at 1650-1660 cm⁻¹, 1610-1640 cm⁻¹, and 1640-1650 cm⁻¹, respectively. Experimental data revealed that the β-sheet signal, initially present at 1610 cm⁻¹ in the native protein, shifted to 1643 cm⁻¹ and 1650 cm⁻¹ in the BMP-2 hydrogel and BMP-2 / HA hydrogel, respectively. This shift indicates a transformation of β-sheets into random coils during the gelation process, likely due to protein unfolding induced by heat and DTT treatment. In particular, the S-H peak in the 2500-2600 cm⁻¹ region, which is typically weak due to the presence of a single free sulfhydryl group at position 78, is notably enhanced upon the addition of dithiothreitol (DTT). This enhancement results from the cleavage of disulfide bonds within the cysteine knot of BMP-2 and the subsequent reduction of these bonds to free -SH group. In contrast, the S-H peak in the BMP-2 / HA hydrogel disappeared entirely. This absence likely reflects the formation of disulfide bonds within the composite hydrogel, indicating successful cross-linking and structural changes. Further, the Fourier Transform Infrared (FTIR) spectra of native protein and the hydrogels are measured using the Shimadzu IRAffinity-1 spectrometer. Approximately 40 μL of the protein sample and a small portion of the hydrogel is taken for measuring the IR spectra. The range for which the IR spectra is scanned and taken as the 400 cm-1 to 4000 cm-1 with high resolution of 2 cm-1. All the samples are prepared using D2O instead of H2O as the medium to discard 1645 cm-1 peak of the H-O-H stretching. Fig. 3A and Fig. 3B illustrates time sweep rheological analysis of BMP-2 hydrogel and BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 3C and Fig. 3D illustrates angular frequency sweep rheological analysis of BMP-2 hydrogel and BMP-2 / HA hydrogel according to embodiments as disclosed herein. Fig. 3E and Fig. 3F illustrates the complex viscosity of the BMP-2 hydrogel and BMP-2 / HA hydrogel with respect to frequency according to embodiments as disclosed herein. Now referring to Fig. 3A- Fig. 3F depicting rheological analysis of BMP-2 and BMP-2 / HA hydrogels according to embodiments as disclosed herein. In particular, the rheological characteristics-encompassing viscosity, as depicted by the flow curve, and the storage and loss moduli, as measured during amplitude sweep tests-are of paramount importance for hydrogel characterization. Dynamic oscillatory measurements, encompassing amplitude sweep and frequency sweep tests, facilitate the evaluation of microstructural attributes such as crosslinking density within a gel or the degree of interaction within a dispersion. These tests probe the material's elastic behavior, characterized by the storage modulus (G'), and its viscous behavior, represented by the loss modulus (G"). Further, a frequency sweep is a method used to investigate how a material's viscoelastic properties vary with changes in frequency. During a frequency sweep, the material is subjected to oscillatory stress or strain at varying frequencies while keeping the amplitude constant allowing assessment of both the storage modulus (G') and the loss modulus (G'') across a range of frequencies. In both the cases the storage modulus (G') remained higher than that of loss modulus (G''), this suggests the composite and the BMP-2 solution formed cross linking forming hydrogel. However, in case of BMP-2 / HA composite hydrogel the storage modulus (G') is lower than that of the BMP-2 hydrogel which symbolizes the lesser crosslinking, which could be due to the intervening HA molecules in the crosslinking process. As the HA molecules are mostly non- interacting species they just intertwine with the cross linked BMP-2 structure, leading to higher loss modulus in the composite one than that of the only protein hydrogel. In a typical embodiment, the rheological analyses, including time and frequency sweep experiments, are conducted using a compact modular rheometer (Anton Paar, MCR 102e) fitted with a cone-plate geometry (CP 25) as the upper plate. These investigated the influence of shear rate on shear stress and viscosity. Frequency sweeps is carried out across a range of 1 to 100 rad / s to assess the viscoelastic properties of the hydrogels at 25 °C. The strain amplitude is held constant at 1%, remaining within the Linear Viscoelastic Region (LVER) established from amplitude sweep tests. The angular frequency-dependent storage modulus (G') of the gels is analyzed using a Power Law model. equation (2) In this context, K and n are empirical constants whose values are specific to the material being tested. The parameter (n) describes how the storage modulus (G') varies with angular frequency (ω). In an embodiment, a low n value, approaching zero, indicates minimal dependence of G' on ω, suggesting that the hydrogel exhibits strong gel network characteristics and excellent gelling properties. In alternative embodiment, a higher n value implies a greater dependence of G' on ω, indicating that protein forms a weaker gel structure. Further, the constant K serves as a proportionality factor and is directly related to G'. A high K value corresponds to an increase in G'. Data analysis is performed using RheoCompass software, and graphical representations are created with OriginLab. Fig.4 A, Fig. 4B and Fig 4C shows swelling characteristics of BMP-2 and BMP-2 / HA hydrogels in double-distilled water, PBS buffer (pH 7.4) and simulated wound fluid according to embodiments as disclosed herein. Fig.4 D shows a histogram of swelling behavior between water and simulated wound fluid according to embodiments as disclosed herein. Referring to Fig. 4A-4D, swelling is a crucial property of hydrogels, as it facilitates water retention at the wound site. The swelling test is carried out in both BMP-2 and the BMP-2-HA composite. It results in the higher water holding / higher swelling capacity of the BMP-2-HA composite. The protein hydrogel exhibited a swelling capacity of 275% within just one hour (Fig. 4A). In contrast, the composite hydrogel demonstrated a swelling of 325% ((Fig. 4B.) over the same period, highlighting its superior water retention properties. This enhanced swelling and water-holding capacity may be attributed to the inclusion of hyaluronic acid, which has an exceptional affinity for water, capable of retaining up to 1000 times its own weight in water. When similar experiments are conducted in a phosphate-buffered saline (PBS) solution at pH 7.4, the swelling percentages are lower compared to those in distilled water. Additionally, swelling tests performed with simulated wound fluid showed increased swelling for both types of hydrogels. Notably, the BMP-2 / HA hydrogel exhibited a significantly greater swelling percentage (~425%) compared to the BMP-2 hydrogel, underscoring its potential utility in wound healing applications ((Fig. 4D.). Fig. 5A and Fig. 5B demonstrates FESEM characterization of BMP-2 hydrogel and of BMP-2 / HA composite hydrogel according to embodiments as disclosed herein. Lyophilized hydrogels are taken for the morphological analysis in Field Emission Scanning Electron Microscope [FESEM]. The FESEM data showed that both the hydrogels had a porous surface. Subsequently the pore size of the BMP-2 hydrogel showed (Fig. 5A) small but the pore size of the BMP-2-HA composite is larger than that of BMP-2 hydrogel (Fig. 5A). The surface morphology of hydrogels (BMP-2 and BMP2-HA composite) are examined by using FEI NOVA NanoSEM 450 equipment operating at an acceleration voltage of 20 kV in secondary electron mode. The energy dispersive X-ray spectroscopy (EDX) along with elemental mapping images are obtained using an Oxford EDS detector attached as an accessory to the FESEM instrument. Fig. 5C demonstrates pore size distribution diameter of the pores of BMP-2 hydrogel and BMP-2 / HA composite hydrogel according to embodiments as disclosed herein. The average pore size in the BMP-2 hydrogel is approximately (1 ± 0.05) μm, while the BMP-2 / HA composite hydrogel exhibited an average pore size of about (15 ± 2) μm (Fig. 5C). Additionally, the surface profile of the BMP-2 hydrogel is rougher compared to that of the composite hydrogel. Fig. 6A demonstrates hemocompatibility evaluation of hydrogels having absorbance intensities at 540 nm and Fig. 6B demonstrates visual comparison of samples after hemolysis testing according to embodiments as disclosed herein. In particular, hemolysis is the process by which red blood cells (erythrocytes) are destroyed and their contents, primarily hemoglobin, are released into the surrounding fluid, such as blood plasma 47. Hemolysis may arise from a range of physiological or pathological factors, including mechanical stress, osmotic stress, oxidative stress, as well as exposure to toxins and pharmacological agents. Further, hemolysis, the rupture of red blood cells (RBCs) and the release of hemoglobin into the surrounding solution, can be quantitatively analyzed using UV-Visible spectroscopy. This technique provides insight into the extent of hemolysis by measuring the absorbance of hemoglobin at specific wavelength of 540 nm, which corresponds to the Soret band of hemoglobin , which is indicative of the concentration of hemoglobin in the supernatant. In accordance with an embodiment of the present invention, to use the hydrogel in wound healing they must be hemo-campatible. Thus, hemolysis test is used to examine the biocompatibility with the blood. When the hydrogels are incubated with the fresh blood, both the hydrogels showed significant non-hemolytic effect. However, the BMP-2 / HA composite hydrogel is found to be more hemo-compatible than the other. In accordance with an embodiment of the present invention, for hemolysis test 1ml of blood sample is taken in a centrifuge tube containing 150 μL citric acid to prevent coagulation. Then the sample is made to a volume of 1.5 ml then centrifuged at 3700 rpm for ten minutes. The same process is carried out thrice to separate the RBC from the whole blood. Then the RBC settles down which is further diluted to 15 ml. Subsequently 200 μL of this sample and 800 μL of the hydrogel are thoroughly mixed and left on a gel rocker for three hours. Then the solution are subjected to a centrifugation of 9800 rpm. The supernatants are taken for absorbance spectroscopic experiments. The absorbance at 540 nm is taken for the final analysis. Fig. 7A illustrates a pictorial snapshot of Trypan blue biocompatibility assay showing gut cell viability in Drosophila larvae according to embodiments as disclosed herein. Fifteen third instar larvae are collected from each experimental and control vial and rinsed thoroughly with 1x PBS to remove food debris. The larvae are then transferred to a 1.5 mL Eppendorf tube containing 1 mL of 0.2% trypan blue solution (Sigma-Aldrich, Merck, Germany; Cat. No. 93595) and incubated in the dark for 25-40 minutes. Following incubation, the dye solution is discarded, and the larvae are dished 2-3 times with 1x PBS to remove residual dye from the larval surface. Images of the transparent larvae are captured under a stereo microscope (MOTIC SMZ171) with a focus on the gut, following the protocol described by Murmu et al. (2023). In a typical embodiment of the present invention, any toxic compound if ingested orally by drosophila is supposed to damage the gut plasma membrane. The further toxic consequences include damaged gut plasma membrane, ROS production and cell death. To check the toxicity of the desired compound trypan blue assay is performed. Live cell plasma membrane has a tendency to efflux out any toxic dye ingested via diet, while if there is cell death at some part of the plasma membrane the region of the gut tissue cannot efflux out the dye and appear blue in colour indicating dead cell. Results of the trypan blue dye suggests there is no blue colouration at any region of the larval gut which can be visible from the transparent larvae. The above results suggest our desired compounds BMP, and BMP-HA, are nontoxic to the gut plasma membrane. Further, different embodiments of the present invention utilized the Oregon R strain of Drosophila, obtained from the C-CAMP Fly Facility in Bangalore, India. Methyl paraben and propionic acid are added to the flies' typical diet of 0.15 M sucrose, cornmeal, yeast, and type I agar to prevent the growth of bacteria and fungi. Five females for every three males are kept in specially designated vials, and they are kept in controlled environments with a 12-hour light / dark cycle, a constant temperature of 25 °C, and 60% relative humidity. Stock solutions of aggregated and disaggregated protein using ionic liquid are prepared in distilled water, and 500 μL of this solution is subsequently mixed into 5 mL of fly food. Fig. 7B illustrates a pictorial snapshot of AO-ETBR assay to detect the cell death according to embodiments as disclosed herein. Following fixation and washing, the dissected gut samples are incubated with 30 μL of Acridine Orange (AO) at a working concentration of 1 μg / mL for 10 minutes. Afterward, the samples are dished and subsequently stained with 20 μL of Ethidium Bromide (EtBr) at a working concentration of 1 μg / mL. This is followed by an additional washing step with a phosphate buffer for 5 minutes. The samples are then mounted using 20% glycerol, and regions of cell death are visualized using a confocal microscope In an embodiment of the present invention, the results of DAPI staining indicates no nuclear fragmentation in the larval gut after feeding with BMP-HA, as the nucleus are proper round in shape. While there are some nuclear fragmentations in case of BMP. The intensity of green fluorescence in case of DCFH-DA staining indicates the amount of Reactive Oxygen Species (ROS) accumulation. Fig. 7C illustrates a pictorial snapshot of DAPI- DCFH-DA assay to detect nuclear fragmentation and ROS generation according to embodiments as disclosed herein. A total of 10-15 larvae from each concentration group are dissected to isolate the gut tissues, which are subsequently fixed in ice-chilled 4% paraformaldehyde (PFA) for 30 minutes. After fixation, the PFA is removed, and the gut samples are washed three times with 1x PBS, each lasting 10 minutes. To enhance dye permeability through the gut plasma membrane, the samples are treated with 1% Tween for 10 minutes twice. Next, 20 μL of DCFH-DA dye (1 μg / mL working concentration; Sigma-Aldrich, Merck, Germany, Cat. No. D6883) is added to the Eppendorf tube containing the gut samples and incubated for 30 minutes, with the tubes covered in aluminum foil to protect from light exposure. After incubation, the dye is discarded, and the samples are washed twice with 1x PBS. Subsequently, 5 μL of DAPI (1 μg / mL working concentration; Sigma-Aldrich, Merck, Germany, Cat. No. D9542) is added to stain the samples, which are incubated in the dark for 5 minutes. The samples are then mounted on clean slides using 20% glycerol, following the protocol described by Kumar et al. (2023). Final imaging is performed using a confocal microscope (Leica DMI8). The gut samples of BMP and BMP-HA fed larvae have the same level of green fluorescence to that of the control samples indicating no major production of ROS. In an embodiment of the present invention, to confirm the results of cell death we stained the dissected gut of 3rd instar larvae fed with BMP and BMP-HA, at 1mg / ml concentration, acridine orange and ETBR staining is performed. The region of gut having apoptotic cell death is supposed to appear with increased fluorescence and bright dots. The merged images of the acridine orange and ETBR staining must appear pinkish colour indicating cell death. The results obtained from Fig.7A indicate no such region in case of control larvae gut, while there are some regions showing pink colouration in case of larvae fed with BMP (Fig. 7B). While in-case of the larval gut fed with BMP-HA (Fig. 7C) the results are no different from those of control indicating no cell death after feeding. Fig. 8A illustrates pictorial snapshots of wound healing in Drosophila melanogaster and Fig. 8B illustrates quantitative plot representation of wound closure percentage over time according to embodiments as disclosed herein. The wound healing efficacy of the BMP-2 / HA and BMP-2 hydrogel is evaluated using a wound model, D. melanogaster, that allows for real-time monitoring of cellular reorganization and morphological changes at the wound site. The formation of cellular structures, including actin cables and filopodia projections, serves as visible indicators of active wound repair processes at the wound periphery. As depicted in Figure 8A, the presence of the hydrogels led to a notable increase in the number of epithelial cells within the wound area, underscoring the effective wound healing properties of both the BMP-2 hydrogel and the BMP-2 / HA composite hydrogel. The initial wound formation is characterized by the secretion of hemolymph. Within the first hour post-injury, the migration of multinucleate cells through cell-to-cell fusion leads to the clotting of hemolymph, marking the commencement of the healing process. In an embodiment of the present invention, after one hour of healing process the control did not make any significant progress in the wound healing process. However, in alternative embodiment the fly treated with the BMP-2 / HA composite hydrogel shows significant wound area shortening. It is about 59 % of the wound area closing. The BMP-2 protein hydrogel showed an average 25% wound area closing. Further, after five hours lapsed the wound healing process is found to be much faster in the case of BMP-2 / HA composite which is about 94-97%. But in the case of control and the BMP-2 only hydrogel showed near about 60-65 % of the wound closure. In accordance with an embodiment of the present invention, the efficacy of synthesized BMP-2 hydrogel and BMP-2-HA hydrogel for in vivo wound healing is assessed using Drosophila melanogaster and compared to a control group. Adult flies, approximately 4-5 days old, are utilized in the experiment, with ten flies per group (Control and treatment groups). The flies are briefly anesthetized with diethyl ether for 30 seconds and then secured onto a Petri dish using adhesive gum. These Petri dishes are subsequently placed under a stereo zoom microscope (MOTIC SMZ171), marking the commencement of the study. A puncture wound, approximately >0.05 mm² in area, is inflicted at the thoracic region of the flies using insulin needles. The test materials are then applied to the wound, and the wound healing process is monitored under the microscope at hourly intervals. The wound closure assay involved measuring wound contraction over a 6-hour period, with assessments conducted every hour using the stereo microscope. Images captured during the observation are analyzed with ImageJ software. Wound closure rates are quantified by evaluating the changes in wound surface area over time.equation (3) Where, A0 and At refer to wound area during time of infliction and at individual time intervals, respectively. The wound area calculation is carried out using sketchandcalc software. Fig.9 demonstrates Cytocompatibility assay (MTT) showing cell viability test of L929 fibroblast cells in the presence of BMP-2 and BMP-2 / HA hydrogels in L292 cell line. The extracts of the hydrogels (BHA and B) are prepared in triplicate and kept for a 24-hour incubation period. It is observed that BHA and B are cyto-compatible as they have shown cell viability greater than 80%. BHA had shown greater cell proliferation than B in the 24-hour incubation period. In accordance with an embodiment of the present invention, the in vitro cytocompatibility of the prepared hydrogels is performed using the MTT assay (ISO 10,993-5) using L929 mouse fibroblast cells. Sterile hydrogels are prepared and immersed in complete media containing 1% antibiotic-antimycotic solution and 10% FBS for 24 hours at 37⁰C to obtain sample extracts. Further, cell seeding is done in a 96-well plate simultaneously, at a density of 105 cells / well, and cells are incubated for 24 hours. After 24-hour incubation, the media of the cells are replaced with the 100% sample extract and kept for 24-hour incubation. Next day, 24 hours later, MTT reagent is added to the cells, which is followed by a 3-hour incubation, and lastly, solubilization reagent is added, and the absorbance is measured at 595nm using a Biorad iMark microplate reader. FIG. 10 illustrates a process flow for preparing the protein hydrogel for wound healing. At (step 1002), the process (1000) comprises, preparing a proteinaceous solution by taking 70 mg / ml of protein from a protein source. Further, at (step 1004), the process (1000) comprises, heating the proteinaceous solution at 850 C for 10 minutes for partially unfolding the protein. Further, at (step 1006), the process (1000) comprises, adding a reducing agent for complete unfolding of the protein by reducing the disulfide bonds; wherein the reducing agent is 200 mM Dithiothreitol. Further, at (step 1008), the process (1000) comprises, aggregating the proteins by stirring at 1000 rpm to form a proteinaceous framework. Further, at (step 1010), the process (1000) comprises, adding hydrogen peroxide to the solution for the crosslinking of the protein through the oxidative crosslinking process; wherein concentration of hydrogen peroxide is 200 mM. Further, at (step 1012), the process (1000) comprises, incorporating hyaluronic acid within the proteinaceous framework to form a composite protein glycan hydrogel. The various actions in process (1000) may be performed in the order presented, in a different order, or simultaneously. Further, in some embodiments, some actions listed in FIG. 10 may be omitted.ADVANTAGEOUS EFFECT OF THE INVENTION In various embodiments of the present invention, the protein hydrogel offers multiple performance advantages over conventional wound healing materials, have enhanced water-holding capacity, which ensures prolonged moisture retention at the wound site for optimal tissue repair. The protein hydrogel has improved cell survival rates, accelerating wound closure and regeneration; Further, the protein hydrogel has superior hemocompatibility, minimizing adverse blood-material interactions and promoting safer in vivo application. Additionally, the protein hydrogel supports enhanced bone cell viability, thereby extending its functional scope to bone tissue engineering and orthopedic repair. The protein hydrogel has higher porosity that facilitates efficient nutrient and oxygen diffusion, site removal, and cell infiltration, collectively contributing to faster healing dynamics and more robust tissue integration. The protein hydrogel has enhanced porosity, superior water-holding capacity, and improved hemocompatibility, while preserving its inherent gelation characteristics. Furthermore, the protein hydrogel exhibits markedly increased swelling behavior in water, pH 7.4 buffer, and simulated wound fluid. The protein hydrogel demonstrated reduced cytotoxicity and neurotoxicity, as evidenced by diminished nuclear fragmentation in DAPI staining assays and lower reactive oxygen species (ROS) generation in DCFH-DA staining analyses. Moreover, the incidence of cell death was significantly decreased compared to that observed with protein-only hydrogels. The protein hydrogel exhibited superior and accelerated wound healing in the model organism Drosophila melanogaster. Additionally, it supported enhanced survival of MG63 cells compared to the protein-only hydrogel. All experiments are conducted in triplicates, with results presented as the mean values of these triplicates accompanied by standard deviations. Statistical analysis is performed utilizing the Student's t-test in SPSS software, with significance thresholds set at p < 0.01 (**) and p < 0.05 (*). Pairwise comparisons are executed, assuming two independent groups for all statistical evaluations. It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient. Still, such omissions and substitutions are intended to cover the application or implementation without departing from the spirit or scope of the present invention. The foregoing descriptions of specific embodiments of the present invention have been presented for purposes of description. They are not intended to be exhaustive or to limit the present invention to the precise forms disclosed, and many modifications and variations are possible in light of the above teaching.Further, the embodiments are chosen and described to best explain the principles of the present invention and its practical application, and thereby enable others skilled in the art to best utilize the present invention and various embodiments with various modifications as are suited to the particular use contemplated.
Claims
1. A protein hydrogel for wound healing comprising: (a) a primary structural framework of a proteinaceous matrix, wherein the proteinaceous matrix comprises unfolded and aggregated proteins; and (b) a glycan encapsulated within the proteinaceous matrix for imparting growth factor-binding capability and enhanced osteogenic potential to support bone cell proliferation and regeneration, wherein the protein hydrogel exhibits enhanced porosity, superior water-holding capacity, and improved hemocompatibility.
2. The protein hydrogel as claimed in claim 1, wherein the glycans is hyaluronic acid (HA).
3. The protein hydrogel as claimed in claim 1, wherein the protein hydrogel is a composite protein glycan hydrogel imparts growth factor-binding capability and enhanced osteogenic potential to support bone cell proliferation and regeneration.
4. The protein hydrogel as claimed in claim 3, wherein the protein hydrogel is a protein hyaluronic acid (HA) hydrogel.
5. The protein hydrogel as claimed in claim 3, wherein the protein hydrogel is a transparent hydrogel.
6. The protein hydrogel as claimed in claim 1-5, wherein the protein hydrogel exhibits increased swelling behavior in water, physiological buffer at pH 7.4 and simulated wound fluid, and wherein the hydrogel demonstrates reduced reactive oxygen species (ROS) generation in DCFH-DA staining analyses.
7. A process for synthesizing a protein hydrogel, the process comprising: preparing a proteinaceous solution by taking 50-70 mg / ml of protein from a protein source; heating the proteinaceous solution at about 50-850 C for about 10 minutes for partially unfolding the protein; adding a reducing agent for complete unfolding of the protein by reducing the disulfide bonds; aggregating the proteins by stirring at an rpm of about 800-1000 rpm to form a proteinaceous framework; adding hydrogen peroxide to the solution for the crosslinking of the protein through the oxidative crosslinking process; incorporating hyaluronic acid (HA) within the proteinaceous framework to form a composite protein glycan hydrogel, wherein the protein hydrogel exhibits enhanced porosity, superior water-holding capacity, and improved hemocompatibility.
8. The process as claimed in claim 7, wherein adding a reducing agent comprises adding 150-200 mM Dithiothreitol.
9. The process as claimed in claim 7, wherein adding hydrogen peroxide to the solution comprises keeping concentration of hydrogen peroxide to about 150-200 mM.
